Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | NFATC1 | O95644 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.42 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898333 | 0.87 | HTR6 (0.59) | CSNK2A1DYRK1AGSK3BNFATC1GPR84 | |
| SCHEMBL3221770 | 0.77 | DYRK1A (0.51) | DYRK1AGSK3BNFATC1GPR84HTR6 | |
| SCHEMBL30768344 | 0.77 | HASPIN (0.62) | DYRK1AGSK3BNFATC1GPR84HTR6 | |
| SCHEMBL29521038 | 0.75 | MEN1 (0.62) | CSNK2A1GPR84HTR6 | |
| SCHEMBL149254 | 0.75 | MEN1 (0.62) | CSNK2A1GPR84HTR6 | |
| SCHEMBL18858475 | 0.75 | HTR6 (0.53) | DYRK1AGSK3BNFATC1GPR84HTR6 | |
| SCHEMBL3899319 | 0.75 | HTR6 (0.76) | DYRK1AGSK3BNFATC1HTR6 | |
| SCHEMBL31036068 | 0.75 | HTR6 (0.76) | DYRK1AGSK3BNFATC1HTR6 | |
| SCHEMBL3924792 | 0.75 | GSK3B (0.53) | DYRK1AGSK3BNFATC1GPR84HTR6 | |
| SCHEMBL22482294 | 0.74 | CCNT1 (0.62) | DYRK1AGSK3BNFATC1PDPK1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3612030-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Kyn Therapeutics (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | KYN THERAPEUTICS (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | KYN THERAPEUTICS (US) | 2020-02-25 | — | — | US | disclosed |
| CN-110831600-A | Indole AHR inhibitors and uses thereof | 金恩医疗公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20180327411-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| WO-2018195397-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | KYN THERAPEUTICS (US) | 2018-10-25 | — | — | WO | disclosed |
| WO-2017143134-A1 | FXR MODULATORS AND METHODS OF THEIR USE | ALIOS BIOPHARMA, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017143134-A1 | FXR MODULATORS AND METHODS OF THEIR USE | ALIOS BIOPHARMA, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327411-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CSNK2A1 2450/4885DYRK1A 1156/4885GSK3B 489/4885 |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CSNK2A1 2450/4885DYRK1A 1156/4885GSK3B 489/4885 |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CSNK2A1 2450/4885DYRK1A 1156/4885GSK3B 489/4885 |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CSNK2A1 2450/4885DYRK1A 1156/4885GSK3B 489/4885 |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CSNK2A1 2450/4885DYRK1A 1156/4885GSK3B 489/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CSNK2A1 2450/4885DYRK1A 1156/4885GSK3B 489/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CSNK2A1 2450/4885DYRK1A 1156/4885GSK3B 489/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CSNK2A1 2450/4885DYRK1A 1156/4885GSK3B 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.